Global Microbiome Therapeutics Market Grows Tremendously at a CAGR of 24.8%

Introduction

Microbiome therapies have attracted considerable interest from the medical community due to their potential to treat unmet medical needs in various clinical disorders. In this digital age, where information is readily accessible, the general populace has become increasingly aware of their medical conditions and treatment alternatives. The modern population seeks safer and more natural products that can address their clinical difficulties and unmet needs, given that the most accessible treatments are chemical compositions with some undesirable side effects. The origin of microbiome therapies may be traced back to 1900 when Joseph Lister isolated Lactococcus lactis from milk. These products currently have a role in the therapeutics market.

Market Dynamics

Growing Strategic Activities in Microbiome Therapeutics Segment Drives the Global Market

In the market for microbiome-based treatments, there have been critical strategic actions. According to the most recent three-year data from 2019 to 2021, there have been 21 finance operations, 22 agreements, and ten regulatory activities. As the microbiome therapeutics industry evolves in response to new research findings, companies are realigning to optimize their available resources, as seen by increased regulatory activity and contracts. Finch Therapeutics Group, Inc. and Takeda have agreed to create FIN-524/TAK-524. Concurrently, Rebiotix Inc. collaborated with Mybiotics to create live microbiota-based therapies for treating bacterial vaginosis in women of reproductive age. Rebiotix Inc. also partnered with CoreBiome for its RBX-2660 and RBX-7455 devices. Rebiotix Inc., Second Genome, 4D pharma plc, and YSOPIA Bioscience are among the microbiome-focused companies.

Growing Disease Dimension Creates Tremendous Opportunities 

In the past decade, there has been a tremendous surge in research activity, with new indications being examined for the function of microbiome therapies. The market sentiment in favor of microbiome therapeutic goods has been bolstered by the potential role of the microbiome in addressing cancer and related issues affecting patients' quality of life (QoL). Several firms are investigating using their products in conjunction with immune checkpoint inhibitors to prevent cancer consequences, which creates an opportunity for both consumers and payers. In addition, the research emphasizing the significance of microbiome therapies in neurological illnesses has opened up new avenues. Although these findings are considered preliminary, the observations reported to date suggest that the gut microbiota can provide the opportunity to identify patients who are more likely to respond to treatment, with the ultimate goal of improving existing therapeutics and developing novel therapeutic strategies. As more and more indications are added, the illness dimension expands, eventually offering potential therapeutic options to the target patients and companies doing their study.

Regional Insights

Asia-Pacific is the highest revenue contributor and is estimated to exhibit a CAGR of 24% during the forecast period. The increasing frequency of chronic diseases, the rapidly aging population, and the growing popularity of treatment processes with common side effects are the primary reasons driving the rise and adoption of innovative microbiome therapeutics solutions. In addition, government funding and investments by both public and private entities increase microbiome-related research activity. Demographics and rapid economic growth in the region are two crucial variables that have played a strong effect in establishing the microbiome business in the area.

Europe is anticipated to grow at a CAGR of 23.1% during the forecast period. Europe is experiencing an increase in the commercialization of innovative therapeutic medicines to treat various indications. Increasing healthcare budget allocation and continuous research to generate breakthrough microbiome therapeutic-based products are key growth drivers for the European microbiome therapeutics market. A European Commission analysis of CORDIS and the EU Open Data Portal revealed, according to a report published by the Microbiome Society, that between 2007 and 2015, the European Commission's FP7 and Horizon 2020 research and innovation programs funded 535 microbiome-related projects at a total cost of USD 1.5 billion. The market for microbiome therapies in Europe is anticipated to expand due to increased clinical research efforts, product approvals, and commercialization in various European nations.

Key Highlights

• The global microbiome therapeutics market was worth USD 380 million in 2022 and is estimated to reach an expected value of USD 2,400 million by 2031, growing at a CAGR of 24.8% during the forecast period (2023 – 2031).
• By target therapy area, the global microbiome therapeutics market is divided into gastrointestinal and infectious diseases, skin disorders, cancer, and other indications. The gastrointestinal and infectious disease segment dominated the market and is estimated to exhibit a CAGR of 24.7% during the forecast period. 
• Asia-Pacific is the highest revenue contributor and is estimated to exhibit a CAGR of 24% during the forecast period.

Competitive Players

Competitive Analysis

The global microbiome therapeutics market key players include 4D pharma plc, Seres Therapeutics, Inc., Microbiotica, Enterome, Destiny Pharma plc, Taisho Pharmaceutical Holdings, AOBiome Therapeutics, Inc., Finch Therapeutics Group, Inc. Ferring Pharmaceuticals, Rebiotix Inc., Maat Pharma, and Vedanta Biosciences Inc.

Recent Developments

Market News

• In February 2023, a leading provider of microbiome therapeutics, Seres Therapeutics, Inc. announced the publication of data from its Phase 3 ECOSPOR IV trial (ClinicalTrials.gov Identifier: NCT03183128) in JAMA Network Open that support earlier findings from the Phase 3 ECOSPOR III study on the investigational microbiome therapeutic SER-109 for the avoidance of recurrent C. difficile infection (rCDI).

Segmentation

Global Microbiome Therapeutics: Segmentation

By Target Therapy Area

• Gastrointestinal and Infectious Diseases
• Skin Disorders
• Cancer Indications
• Other Indications

By Regions

• North America
• Europe
• Asia-Pacific 
• Rest of the World